mouse monoclonal antibody to cdk7  (Cell Signaling Technology Inc)

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: CDK7 overexpression in epithelial ovarian cancer and its clinicopathologic significance. (A) Representative images of immunohistochemical staining of CDK7 in ovarian tissues from normal, benign, borderline, and high-grade serous carcinoma patients. High magnification images are shown in inset. N, normal; Be, benign; Bo, borderline; EOC, epithelial ovarian cancer. Scale bar shown is 50 μm. (B) Boxplot of CDK7 expression according to pathological characteristics. N, normal (n = 62); Be, benign (n = 69); Bo, borderline (n = 57); EOC, epithelial ovarian cancer (n = 197); Mets, metastasis (n = 51), Gr1/2; grade 1/2, Gr3; grade 3. (C) Kaplan-Meier plots of progression-free survival and overall survival according to CDK7 expression. of CDK7High, high CDK7 expression; CDK7Low, Low CDK7 expression.

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques: Over Expression, Immunohistochemical staining, Staining, Expressing

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: Univariate and multivariate analyses of progression-free survival and overall survival according to prognostic variables in ovarian cancer patients (n = 192).

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques:

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: (A) Western blot analysis of CDK7 in various epithelial ovarian cancer cell lines. (B) Effect of THZ1, a covalent CDK7 inhibitor, on EOC cell proliferation in A2780, HeyA8, RMG-1, and A2780-CP20 cells after 48 and 72 h. Each line represents an individual cell viability curve (square: 48 h; triangle: 72 h). THZ1 significantly reduced the proliferation of A2780, HeyA8 and RMG-1 cells in a dose-dependent manner in both 48 and 72 h, and this anti-proliferative effect of THZ1 was observed more significantly at 72 h exposure in A2780, HeyA8 and RMG-1 (40 nM: 79.0% vs. 69.0% (P = 0.012); 60 nM: 67.0% vs. 53.0% (P < 0.001)) cells compared with 48 h. Representative images of cell proliferation from the MTT assay after THZ1 treatment (40 nM, 48 h) are also shown above. (C) Synergistic effect of THZ1 with cisplatin on EOC cell proliferation in A2780-CP20 cells. Cell proliferation was significantly decreased by treatment with 40 nM THZ1 and cisplatin. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques: Western Blot, MTT Assay

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: (A) Apoptosis increased dose dependently after treatment with THZ1 in A2780, HeyA8, and RMG-1 cells but not in A2780-CP20 cells. (B, C) Wound healing assay after treatment with THZ1 (40 nM) in A2780 and RMG-1 cells. Inhibition of CDK7 interfered with the migratory ability of EOC cells. All photographs were taken at 100X magnification. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques: Wound Healing Assay, Inhibition

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: Effect of THZ1 in cell cycle control of EOC cell lines. (A) Flow cytometry analysis in A2780 cells treated with THZ1. (B) THZ1 induces G0/G1 cell cycle arrest in A2780 cells. (C) Western blot analysis of CDKs (CDK4 and CDK7) and cyclins (cyclin D1 and cyclin H) in A2780 and HeyA8 cells treated with THZ1. CDKs and cyclins decreased after THZ1 treatment in a dose-dependent manner. *P < 0.05, **P < 0.01.

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques: Control, Flow Cytometry, Western Blot

Journal: Gynecologic oncology

Article Title: CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

doi: 10.1016/j.ygyno.2019.11.004

Figure Lengend Snippet: Effect of CDK7 inhibition from THZ1 on tumor weight, cell proliferation, and apoptosis in in vivo experiments with EOC cell line xenograft and patient-derived xenograft models. (A) THZ1 significantly decreased tumor weight, compared with control. (B) In the THZ1-treated group of A2780 cells, the harvested tumor tissues showed significantly reduced cellular proliferation and increased apoptosis. (C) THZ1 significantly reduced tumor weight compared with the DMSO-injected control in the PDX model. (D) In each image, a normal kidney (left) and a developed PDX (right) are shown. (E) In the PDX model, harvested tumor tissues showed significantly decreased the Ki-67 proliferative indices and increased apoptosis in the TUNEL assay. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: The sections were incubated with anti-CDK7 mouse monoclonal antibody (clone M01; Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution for 60 min at room temperature.

Techniques: Inhibition, In Vivo, Derivative Assay, Control, Injection, TUNEL Assay